FDA product code LTJ: Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers
LTJ is the FDA product code for prostate-specific antigen (psa) for management of prostate cancers. It is a Class II device, regulated under 21 CFR 866.6010 and reviewed by the Immunology panel. FDA has cleared 34 510(k) submissions under LTJ, 1 in the last five years, from 20 different applicants. The average 510(k) review took 122 days (median 88); 222 days on average over the last three years. 9 PMA applications cite this product code. FDA has posted 12 recalls for LTJ devices, 1 initiated in the last five years.
Classification
| Field | Value |
|---|---|
| Device name | Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers |
| Device class | Class II |
| Regulation | 21 CFR 866.6010 |
| Review panel | IM — Immunology |
| Medical specialty | Immunology |
| Premarket route | 510(k) |
| Third-party 510(k) review eligible | Yes |
510(k) clearances per year for LTJ
| Year | Clearances | Avg. review days |
|---|---|---|
| 2017 | 1 | 266 |
| 2026 | 1 | 222 |
Compare with all 510(k) review times · Search every LTJ clearance
Top LTJ applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Boehringer Mannheim Corp. | 5 | 1998-10-27 |
| Bayer Corp. | 4 | 2002-12-17 |
| Diagnostic Products Corp. | 3 | 1998-04-21 |
| Dade Behring, Inc. | 2 | 2003-05-15 |
| Oncogene Science, Inc. | 2 | 2000-08-30 |
15 more applicants have LTJ clearances. See the full list in Caduvo.
Most recent LTJ clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K251630 | Siemens Healthcare Diagnostics, Inc. | Atellica IM Total PSA II (tPSAII) | 2026-01-05 | 222 |
| K162378 | Nanoentek USA, Inc. | FREND PSA PLUS (reagent cartridge) | 2017-05-17 | 266 |
| K124056 | Nanoentek, Inc. | FREND PSA PLUS (REAGENT CARTRIDGE) | 2013-05-29 | 149 |
| K031343 | Dade Behring, Inc. | TPSA FLEX REAGENT CARTRIDGE | 2003-05-15 | 16 |
| K022288 | Bayer Corp. | COMPLEXED PROSTATE SPECIFIC ANTIGEN (CPSA) ASSAY FOR THE BAYER ADVIA INTEGRATED MODULE SYSTEM | 2002-12-17 | 155 |
Recalls for LTJ devices
12 product recalls in 10 recall events; 1 initiated in the last five years and 1 still open. Most recent: 2025-11-03.
| Year | Recalls |
|---|---|
| 2018 | 1 |
| 2025 | 1 |
Frequently asked questions
What is FDA product code LTJ?
LTJ is the FDA product code for prostate-specific antigen (psa) for management of prostate cancers. It is a Class II device, regulated under 21 CFR 866.6010 and reviewed by the Immunology panel.
What device class is LTJ?
Class II, regulation 21 CFR 866.6010. Typical premarket route: 510(k).
How long does a 510(k) take for product code LTJ?
Across 34 cleared submissions the average was 122 days from receipt to decision (median 88).
Which companies have the most LTJ clearances?
Boehringer Mannheim Corp. (5); Bayer Corp. (4); Diagnostic Products Corp. (3); Dade Behring, Inc. (2); Oncogene Science, Inc. (2).
Have LTJ devices been recalled?
Yes: 12 product recalls across 10 recall events; the most recent began 2025-11-03.
Next steps
- Run an FDA pathway report with predicate devices for product code LTJ
- Run a recall and safety report across every LTJ manufacturer
- Watch product code LTJ for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Immunology product codes · FDA product code lookup · 510(k) database search · 510(k) review times